window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 16, 2025

  • News
  • About Us
Contact Us

solid tumours

  • Biotech,Market Access & Commercialization,Oncology,Partnerships & Funding,Research & Development

    Cue Biopharma and ImmunoScape partner on novel in vivo cell therapy for solid tumours

    Cue Biopharma and ImmunoScape have entered an exclusive collaboration and [...]

    November 6, 2025
  • Biotech,Cell & Gene Therapy,Partnerships & Funding,Research & Development

    MaxCyte signs platform licence with Moonlight Bio to advance T cell therapies for solid tumours

    MaxCyte has entered a strategic platform licence with US biotech [...]

    October 13, 2025
  • Biologics & Biosimilars,Biotech,Oncology,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development

    Synaffix and Qurient partner on dual-payload ADC for solid tumours

    Lonza’s Synaffix has signed a licensing agreement with Qurient Therapeutics [...]

    September 25, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Oncology,Partnerships & Funding

    eXmoor and Signadori Bio partner to advance monocyte-based cell therapy for solid tumours

    New alliance focuses on translation, process development and GMP-readiness for [...]

    July 1, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Drug Development,Oncology,Partnerships & Funding,Technology and platforms

    Mabion manufactures first batch of NovalGen’s bispecific T-cell engager for clinical trials

    Poland-based CDMO Mabion has completed the first GMP-compliant batch of [...]

    June 27, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top